Although the safety of pyrazinamide in pregnancy has not been established, whenever possible the six-month regimen based on isoniazid, rifampicin and pyrazinamide should be used during pregnancy.

The recommended duration of treatment for MDR-TB treatment regimens is guided by culture conversion and other factors such as extent of disease.

WHO recommends continuing therapy for a minimum of 18 months after culture conversion for a total of at least 20 months.